||BX471 is a potent, selective non-peptide CCR1 antagonist.
||NSC5844 (RE640) is a bisquinoline compound with C-C chemokine receptor type 1 (CCR1)-agonistic activities.
||Arteether is a new, fast-acting antimalarial drug.
||ZK 756326 is a selective, non-peptide CCR8 chemokine receptor agonist (IC50: 1.8μM, in human; 2.6 μM, in mouse). Displays no activity at CCR4/5 and CXCR3/4 and shows higher 28-f
||INCB8761(PF-4136309) is a specific, effective, and orally bioavailable CCR2 antagonist.
||Vicriviroc maleate(Sch-417690) is a piperazine-based CCR5 receptor antagonist with activity against human immunodeficiency virus. The IC50 value is 0.91 nM in clinical development
||Maraviroc is a C-C Chemokine Receptor Type 5 (CCR5) antagonist, and for MIP-1α(IC50=3.3 nM), MIP-1β (IC50=7.2 nM) and RANTES(IC50=5.2 nM).Maraviroc inhibits HIV-1 entry via CCR5
||Bindarit displays specific inhibition against monocyte chemotactic proteins MCP-1/CCL2, MCP-3/CCL7 and MCP-2/CCL8.
||AZD2098 is a potent CC-chemokine receptor 4 (CCR4) inhibitor used for asthma research.
||BMS-813160 is the first dual CCR2/CCR5 antagonist to enter clinical development for cardiovascular.
||RS 504393 is a highly selective CCR2 chemokine receptor antagonist (IC50s: 89 nM and > 100 μM for human recombinant CCR2 and CCR1).